Most large studies report recurrent activating genetic alterations involving the classical MAPK signaling pathway in 57% of HS, but only a few reports either BRAFV600E or other BRAF mutations in HS [25, 26]. This evidence concerns the gene BRAF and histiocytic sarcoma.